Nuclear receptor E75/NR1D2 drives tumor malignant transformation by integrating Hippo and Notch pathways

Hormone therapy resistance and the ensuing aggressive progression of tumors present a significant clinical challenge. However, the mechanisms underlying the induction of tumor malignancy by hormone inhibition remain poorly understood. Here we show that Drosophila malignant epithelial tumors exhibit a comparable decrease in ecdysone signaling, the primary steroid hormone pathway in Drosophila. Furthermore, we find that ectopic expression of the nuclear receptor E75 partially mimics ecdysone signaling inhibition, specifically promoting the malignant transformation of benign tumors by integrating the Hippo and Notch signaling pathways. Genome-wide DNA binding profiles and biochemistry data reveal that E75 not only physically interacts with the transcription factors of both Hippo and Notch pathways, but also exhibits widespread co-binding to their target genes, thus contributing to tumor malignancy. Moreover, we validate these findings by demonstrating that depletion of NR1D2, the mammalian equivalent of E75, inhibits the activation of Hippo and Notch target genes, impeding glioblastoma progression in vivo. In summary, our study unveils a previously unrecognized mechanism by which hormone inhibition promotes tumor malignant transformation, while providing a conserved mechanistic understanding of how Hippo and Notch pathways are integrated by the oncogene E75/NR1D2 during tumor progression.